All lobbying filings

TIBER CREEK GROUP

Lobbying for GILEAD SCIENCES, INC. · Discovery, development, commercialization of medicines in areas of unmet medical needs.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 17, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 2213
Medical Supply Chain Resiliency Act
S 998
Medical Supply Chain Resiliency Act

Lobbying activity 4

Trade (domestic/foreign)

Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries.

Health Issues

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Budget/Appropriations

Issues related to HIV prevention and procurement.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.